ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of ARCA biopharma, Inc. (the “Company”) (NasdaqCM: ABIO) and Oruka Therapeutics. Upon closing of the proposed transaction, ARCA shareholders are expected to own approximately 2.38% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether the merger is fair to ARCA shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-abio/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
Lewis S. Kahn, Managing Partner, 855-768-1857
lewis.kahn@ksfcounsel.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240405049369/en/